Hello, and thank you for visiting STCube.

STCube is an innovation-oriented biotechnology company focusing on developing optimal immunotherapies using precision medicine tailored to patients.

Guided by our belief in ‘persistent research and innovation for cancer treatment’, we strive to offer new solutions for treatment resistant/refractory and recurrent cancers.

Cancer has been, and still is, one of the deadliest diseases. STCube is committed to making the lives of patients and their families worldwide better through providing better treatment options.

STCube’s growth is built upon cutting-edge research capabilities and scientific breakthroughs to identify and develop new immunotherapy targets. We have pioneered a new frontier in cancer treatment by developing “Nelmastobart”, the world’s first antibody targeting BTN1A1, and we continue to push the boundaries to deliver faster, safer, and more effective treatments for cancer.

Looking ahead, STCube will continue to explore groundbreaking treatment options and aspire to provide hopes to cancer patients around the world. We appreciate your continued interest and support.

Thank you.